Ben and Yvette have a rather vigorous but hugely engaging conversation with friend of the Pod, Dr. Kimberly Smith, the Head of R&D for ViiV Healthcare, on what’s needed to ensure that the potential of long acting injectable antiretrovirals - for both HIV prevention & treatment - are realized for girls and women in sub-Saharan Africa. With its costs and manufacturing complexity - will CabLA be a truly a game changer or an afterthought?
And Kim promised to check whether the regulatory submission formulation of long-acting cabotegravir and rilpivirine for treatment has been filed in South Africa already: It was, in September 2021.
https://www.croiconference.org
https://www.ashotinthearmpodcast.com
https://viivhealthcare.com
https://www.avac.org
https://apha.org.za
https://medicinespatentpool.org
https://www.niaid.nih.gov
https://www.cdc.gov
https://www.iasusa.org
https://www.unaids.org
https://www.state.gov/pepfar
#CROI_2023 #HIV #prevention #treatment #longacting #CabLA #vaccine #pandemics #access #affordability #techtransfer #voluntarylicense